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Abstract
Background: Despite the growing number of people on antiretroviral therapy (ART), there is limited information
about virological non-suppression and its determinants among HIV-positive (HIV+) individuals enrolled in HIV care
in many resource-limited settings. We estimated the proportion of virologically non-suppressed patients, and
identified the factors associated with virological non-suppression.
Methods: We conducted a descriptive cross-sectional study using routinely collected program data from viral load
(VL) samples collected across the country for testing at the Central Public Health Laboratories (CPHL) in Uganda.
Data were generated between August 2014 and July 2015. We extracted data on socio-demographic, clinical and
VL testing results. We defined virological non-suppression as having ≥1000 copies of viral RNA/ml of blood for
plasma or ≥5000 copies of viral RNA/ml of blood for dry blood spots. We used logistic regression to identify factors
associated with virological non-suppression.
Results: The study was composed of 100,678 patients; of these, 94,766(94%) were for routine monitoring, 3492(4%)
were suspected treatment failures while 1436(1%) were repeat testers after suspected failure. The overall proportion
of non-suppression was 11%. Patients on routine monitoring registered the lowest (10%) proportion of non-
suppressed patients. Virological non-suppression was higher among suspected treatment failures (29%) and repeat
testers after suspected failure (50%). Repeat testers after suspected failure were six times more likely to have
virological non-suppression (ORadj = 6.3, 95%CI = 5.5–7.2) when compared with suspected treatment failures
(ORadj = 3.3, 95%CI = 3.0–3.6). The odds of virological non-suppression decreased with increasing age, with children
aged 0–4 years (ORadj = 5.3, 95%CI = 4.6–6.1) and young adolescents (ORadj = 4.1, 95%CI = 3.7–4.6) registering the
highest odds. Poor adherence (ORadj = 3.4, 95%CI = 2.9–3.9) and having active TB (ORadj = 1.9, 95%CI = 1.6–2.4)
increased the odds of virological non-suppression. However, being on second/third line regimens (ORadj = 0.86,
95%CI = 0.78–0.95) protected patients against virological non-suppression.
Conclusion: Young age, poor adherence and having active TB increased the odds of virological non-suppression
while second/third line ART regimens were protective against non-suppression. We recommend close follow up
and intensified targeted adherence support for repeat testers after suspected failure, children and adolescents.
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Background
The number of people accessing antiretroviral therapy
(ART) has gradually increased in the recent years [1].
With the rising numbers of patients accessing ART, it is
important to sustain treatment success and limit devel-
opment of treatment failure. To allow timely detection
of treatment failures, WHO in July 2013 recommended
use of viral load testing as the gold standard to monitor
patients response to ART [2]. Establishment of the viro-
logical suppression status among patients enrolled on
ART is important for timely detection of treatment fail-
ures, identification of patients in need of more intensive
adherence support and minimizes development of drug
resistance and unnecessary switch to expensive and lim-
ited ART regimen options [3, 4].
The Ugandan guidelines recommend that viral load
testing should be done 6 months after initiating ART
and thereafter annually for people who have achieved
viral suppression. However, people with detectable viral
loads undergo targeted intensified adherence support for
6 months followed by confirmatory viral load testing in
order to differentiate poor adherence from treatment
failure. Those with treatment failure as defined by two
detectable viral load measurements above the threshold
are switched to second-line ART [2].
Previous studies have highlighted a number of factors
that may be associated with virological suppression. Pa-
tients with WHO clinical staging 4 are more likely to be
non-suppressed while those whose health status is evalu-
ated by physicians on each clinic visit are less likely to
experience virological failure [5]. Children and adoles-
cents on ART are more likely to have high viral loads
[6]. Suboptimal adherence, poor tolerability, and drug
and food interactions, CD4 cell count, treatment history
and drug-resistance (primary or transmitted) have also
been associated with virological non-suppression. Sub-
optimal adherence and drug intolerance are the major
cause of regimen discontinuations and hence virological
failure [7–9]. Virological non-suppression may also be
caused by patient-related factors such as co-morbidities,
incomplete medication adherence and missed clinic ap-
pointment and interruption of or intermittent access to
ART, and ARV regimen related factors such as drug ad-
verse effects, suboptimal pharmacokinetics, suboptimal
virological potency and food requirements, amongst
other factors [10].
In 2014 the Joint United Nations Programme on HIV/
AIDS (UNAIDS) set new targets towards elimination of
HIV, including diagnosis of 90% of HIV infected individ-
uals, access to treatment for 90% of identified HIV in-
fected persons, and 90% viral suppression among those
initiated on treatment [11]. These targets have since
been adopted by several countries including Uganda.
Thus, viral load is a critical indicator for HIV treatment
quality and tracking of progress towards national and
global indicators.
Despite the increasing number of HIV+ patients acces-
sing ART [1], there is limited information about non-
suppression rates amongst the different groups of people
enrolled in care in Uganda and many resource limited
settings in general. Studies that have highlighted the fac-
tors associated with virological suppression in most de-
veloped countries and resource limited settings have
used lower cut-offs to determine non-suppression. The
thresholds used range from 300 to 500 copies/ml of
blood [12]. However, since several clinical and epidemio-
logical studies have highlighted the risk of HIV transmis-
sion being very low when the viral load is lower than
1000 copies/ml, WHO recommends using 1000 copies/
ml as the threshold when using plasma and 5000 copies/
ml for dry blood spots (DBS) [2, 13]. Uganda and other
countries such as Swaziland are using the WHO recom-
mended thresholds. Most Ugandan studies that have
assessed viral suppression have been based on small
numbers [14, 15]. Finally, the relative contribution of the
factors leading to virological non-suppression may vary
across settings and population groups and context spe-
cific data are critical to the implementation of corrective
measures. The aim of this study was to estimate the pro-
portion of virologically non-suppressed HIV+ patients
who had been on ART for at least 6 months and identify
factors associated with virological non-suppression using
a large national dataset of routinely collected program
data at the Central Public Health Laboratories (CPHL)
in Uganda between August 2014 and July 2015.
Methods
Study design
This was a descriptive cross-sectional study using a large
national dataset of routinely collected program data
(sample size 100,678) that were submitted to the Central
Public Health Laboratories (CPHL) from all health facil-
ities in Uganda between August 2014 and July 2015.
Study setting
The study was conducted at CPHL where the centralized
VL testing is done in Uganda. Centralized monitoring of
response to ART using viral load as a gold standard
started in August 2014. The samples come from all over
the country from both private and government health fa-
cilities offering HIV ART services. Uganda is located
within the East African region with a population of 34.9
million [16] and a general HIV prevalence of 7.3% [17].
According to the 2014 Uganda HIV and AIDS Country
Progress Report, 1,500,000 people were living with HIV
in 2014 [18]. Of these, 750,896 (50% coverage) were ac-
tive on ART by Dec 2014 [18]. There were 125,705 new
active patients on ART by end of 2014 [18]. According
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to the viral load testing request form version for Uganda,
the three main reasons for viral load testing are: 1) rou-
tine testing; 2) suspected failure, and 3) repeat viral load
testing after suspected treatment failure for patients who
were virologically non-suppressed on first time testing
and underwent enhanced adherence support for 6 months
and submitted a follow-up sample at the end of 6 months.
Study participants and data collection
We used VL testing data for samples corresponding to
HIV positive patients who had been on ART for at least
6 months. Data generated from the start of VL testing at
CPHL in August 2014 to July 2015 were considered for
the study.
Measures
The primary outcome was virological non-suppression,
defined as having ≥1000 copies of viral RNA/ml of blood
for plasma or ≥5000 copies of viral RNA/ml of blood for
dry blood spots [19]. We abstracted data on viral load
testing results (for plasma and DBS) measured in terms
of viral RNA copies/ml of blood, age, sex, duration of
treatment, treatment line (first, second, third), identifica-
tion for treatment initiation at baseline (ePMTCT option
B+, child under 15, CD4 < 500 and TB infection), preg-
nancy status, breast feeding status, having active TB,
health facility level, reasons for viral load testing (routine
monitoring, suspected treatment failure, and repeat VL
test after suspected treatment failure [for patients who
were not suppressed on first time testing underwent en-
hanced adherence support for six months and submitted
a follow up at the end of the six months]).
Data analysis
We analyzed the entire study data set to estimate the
proportion of patients with virological non-suppression,
and to identify factors associated with virological non-
suppression. In-addition, we conducted sub-group ana-
lyses in line with the 3 major reasons for viral load test-
ing in Uganda (routine monitoring of response to
treatment, suspected treatment failure, and repeat viral
load testing after suspected failure). We used univariate
analysis to establish the socio-demographic and clinical
characteristics of the study population, the overall and
group specific proportions of patients with virological
non-suppression. Virological non-suppression propor-
tion was defined as the percentage of the number of
total not suppressed among the total number tested.
The proportion with viorological non-suppression were
further evaluated by age group, gender, duration on
treatment, reported adherence levels, pregnancy status,
breast feeding status, having active TB, treatment line,
reason for VL test (routine monitoring, suspected
treatment failure, and repeat VL test after suspected fail-
ure) and health facility level.
We created the outcome variable of suppression status
by categorizing the viral load results into two groups. All
results <1000 or 5000 copies/ml of blood for plasma and
DBS respectively were categorized as suppressed while
≥1000 or 5000 copies/ml of blood for plasma and DBS
respectively were categorized as not suppressed. At the
exploratory analysis stage, we realized that the percent-
age of variables with missing values was <10% of all the
variables in the data set. Missing values were dropped
automatically from each variable and analysis was con-
ducted based on the totals with complete records.
We used bivariate analysis to determine strengths of
association between the independent variables and the
outcome variable (virological suppression status). Crude
odds ratios (OR) and 95% confidence intervals were cal-
culated. We used multivariate logistic regression to iden-
tify factors independently associated with virological
non- suppression. Adjusted odds ratios (OR) and 95%
confidence intervals were calculated. We considered the
reason for viral load testing (routine monitoring, sus-
pected treatment failures, and repeat testers after sus-
pected treatment failure) in Uganda as the main
exposure variable of interest. We adjusted for age, sex,
ARV adherence, treatment line (first, second/third),
identification for treatment initiation at baseline
(ePMTCT option B+, child under 15, CD4 < 500 and TB
infection), having active TB, duration on treatment, and
health facility level. We dropped the option “other”
under the option for indication for treatment initiation
at baseline when conducting bivariate and multivariate
analysis. This was due to the fact that it was not clear
which categories of patients were categorized as “other”.
In the sub-analyses, age group was considered to be the
main exposure variable of interest. In addition, factors
were entered into logistic regression models based on
biological plausibility, previous literature, and statistical
significance in bivariate analysis. We tested for inter-
action and did not find any statistically significant inter-
action terms to report on. Pregnant and breast feeding
status were excluded from model building because they
only apply to females. Statistical significance was consid-
ered at p-value <0.05 (two-sided). Data were entered into
Excel 2007 and analyzed using Epi-info version 7.
Ethical consideration
We used program data collected for routine patient care
at all health facilities in Uganda and submitted to the
Central Public Health Laboratories (CPHL) which is
mandated to conduct centralized viral load testing in
Uganda. All data did not carry personal identifiers. The
data were not accessible by any other third parties other
than the study team. Permission to use the data was
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sought from the Ugandan Ministry of Health under
whose mandate CPHL falls.
Results
Patients’ characteristics
Table 1 shows the characteristics of the 100,678 patients
whose viral load data were available for analysis. Of
these, 94,766 (94%) were for routine monitoring, 3492
(4%) were for suspected treatment failures while 1436
(1%) were for repeat testers after suspected failure. In
general, females contributed the biggest proportion of
the study sample, ranging from 55 to 68% across the
three patient-subcategories. Most of the patients were
aged 35+ years: 53,489 (56%) among patients for routine
monitoring, 2140 (61%) among suspected treatment fail-
ures and 430(30%) among repeat testers after suspected
failure. Majority of the patients had been initiated on
ART basing on their CD4 < 500, i.e., 70,116 (76%)
among patients for routine monitoring, 2832 (85%)
among suspected treatment failures and 839 (62%)
among repeat testers after suspected failure. All the 3
categories had majority of the patients on first line regi-
mens, i.e., routine monitoring 89,382 (95%), suspected
treatment failures 3177 (92%) and repeat testers after
suspected failure 1070 (75%). Reported adherence
(>95%) was highest among patients for routine moni-
toring 81,478 (89%), followed by repeat testers after
suspected failure 1005 (74%), and lowest among sus-
pected treatment failures 2278 (68%). The proportion
of women who were either pregnant or breast feed-
ing ranged from 1 to 5% across all the 3 patient
categories. Patients with active TB represented only
1–5% of the study sample across all the patient categories.
Proportion of patients with virological non-suppression
Table 2 shows the proportion of patients with overall
virological non-suppression and by the three patient sub-
categories. The overall proportion of virologically non-
suppressed patients in the study sample was 11%. In gen-
eral, repeat testers after suspected failure had the highest
proportion of patients with virological non-suppression
(50%), followed by suspected treatment failures (29%) and
least routine monitoring patients (10%). In-addition, the
proportion of virologically non-suppressed patients were
highest among the repeat testers after suspected failure,
followed by suspected treatment failures and lastly pa-
tients for routine monitoring considering all the variables
explored.
In general, the proportion of virologically non-
suppressed patients decreased with increasing age, with
the highest proportion being 29% for children aged 0–
4 years, followed by 27% for adolescents aged 15–
19 years and least 7% for adults aged 35+ years. The
same trend is observed across the 3 patient sub-
categories. Males (13%) had a slightly higher proportion
of non-suppressed patients compared the females (10%).
Breast feeding (6%) and pregnant (8%) mothers had the
lowest proportion of virologically non-suppressed pa-
tients amongst all the different patient categories ex-
plored. In general, virological non-suppression was
highest amongst patients with reported adherence
levels of <85% (35%) followed by patients with 85–94%
(17%) and least among those with adherence levels
>95% (10%). Regional and National referral hospitals
had the highest proportion of virologically non-
suppressed patients (12%), followed by specialized HIV
care services with 11%, and least health centre IV and
general hospitals, and health centre II and III each
with 9% (Table 2).
Factors associated with virological non-suppression
Table 3 shows the crude and adjusted odds ratios associ-
ated with virological non-suppression by reason for viral
load testing and other background characteristics. At bi-
variate analysis level, the reason for viral load testing was
significantly associated with virological non-suppression:
Suspected treatment failures (ORcrude = 4.2, 95%CI = 3.6–
4.2) and repeat testers after suspected failure (ORcrude = 9.5,
95%CI = 8.6–10) were more likely to be virologically non-
suppressed, compared with routine testers. In addition,
young age was significantly associated with virological
non-suppression: Children aged 0–4 years (ORcrude = 5.1,
95%CI = 4.6–5.7) and adolescents aged 15–19 years
(ORcrude = 4.7, 95%CI = 4.4.4–5.2) were more likely to be
virologically non-suppressed compared with patients aged
35+ years. Patients with reported adherence level < 85%
(ORcrude = 5.1, 95%CI = 4.6.4–5.8) were also more likely
to be virologically non-suppressed compared to patients
with >95% adherence level. Similarly, patients on second/
third line treatment (ORcrude = 1.3, 95%CI = 1.3.4–1.4),
patients with active TB (ORcrude = 2.1, 95%CI = 1.7–2.5)
were also more likely to be virologically non-suppressed.
Pregnancy (ORcrude = 0.77, 95%CI = 0.65–0.91) and breast
feeding (ORcrude = 0.61, 95%CI = 0.54–0.69) were protect-
ive against virological non-suppression (Table 3).
At multivariate analysis level, being a suspected treat-
ment failure (ORadj = 3.3, 95%CI = 3.0–3.6), and repeat
tester after suspected failure (ORadj = 6.3, 95%CI = 5.5–
7.2), being a child aged 0–4 years (ORadj = 5.3,
95%CI = 4.6–6.1), being an adolescent aged 15–19 years
(ORadj = 4.1, 95%CI = 3.7–4.6), having reported adher-
ence level < 85% (ORadj = 3.4, 95%CI = 2.9.4–3.9), and
having active (ORadj = 1.9, 95%CI = 1.6–2.4) were sig-
nificantly associated with increased odds of virological
non-suppression. However, being on second/third line
treatment (ORadj = 0.86, 95%CI = 0.78–0.95) reduced
the odds of virological non-suppression (Table 3).
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Table 1 Socio-demographic and clinical characteristics of patients, August 2014–July 2015 (N = 100,678, routine monitoring, n = 94,766,
suspected treatment failures, n = 3492 and second time testers, n = 1436)
Variable General-N(%) Routine monitoring,
n(%)
Suspected treatment
failures, n(%)
Repeat testers after
suspected failure, n(%)
Age group
0–4 1763(2.0) 1637(1.7) 45(1.3) 65(4.5)
5–9 3983(4.0) 3681(3.9) 111(3.2) 172(11.9)
10–14 4231(4.0) 3898(4.1) 136(3.9) 168(11.6)
15–19 3085(3.0) 2689(2.8) 189(5.4) 180(12.7)
20–24 4781(5.0) 4436(4.7) 176(5.0) 131(9.1)
25–29 10,695(11.0) 10,192(10.8) 257(7.4) 131(9.2)
30–34 15,494(15.0) 14,744(15.6) 438(12.5) 159(11.0)
35+ 56,646(56.0) 53,489(56.4) 2140(61.3) 430(29.9)
Sex
Male 32,203(32.0) 29,873(32.0) 1539(45.0) 515(36.0)
Female 67,097(68.0) 63,598(68.0) 1918(55.0) 900(64.0)
Duration on treatment
0–2 Years 36,341(36.0) 3,4610(36.6) 1002(28.8) 298(20.8)
3–5 Years 32,928(33.0) 30,876(32.7) 1240(35.7) 548(38.3)
6–10 Years 28,423(28.0) 26,533(28.1) 1110(31.9) 534(37.3)
> 10 Years 2726(3.0) 2518(2.7) 125(3.6) 52(3.6)
Indication for treatment initiation
TB infection 4076(4.0) 3721(4.0) 129(3.9) 127(9.4)
Other 1496(2.0) 1392(2.0) 72(2.2) 24(1.8)
Child under 15 9820 (10.0) 9550(10.0) 83(2.5) 59(4.4)
PMTCT/Option B+ 7712(8.0) 7117(8.0) 234(7.0) 300(22.4)
CD4 < 500 74,401(76.0) 70,116(76.0) 2832(84.5) 839(62.0)
Report ARV adherence
< 85% 1292(1.3) 964(1.0) 253(7.5) 62(5.0)
Fair 85–95% 10,065(10.4) 8798(10.0) 832(24.7) 291(21.0)
Good >95% 85,440(88.3) 81,478(89.0) 2278(67.7) 1005(74.0)
Treatment line
First line 94,476(94.45) 89,382(95.0) 3177(92.2) 1070(75.0)
Second line 5497(5.5) 4815(5.0) 264(7.7) 354(25.0)
Third line 50(0.05) 39(0.0) 4(0.1) 4(0.0)
Pregnant
Yes 2009(3.0) 1950(2.0) 27(1.0) 33(2.4)
Breast feeding
Yes 4697(7.0) 4647(5.0) 52(2.0) 35(3.0)
Active TB
Yes 668(1.0) 575(0.6) 77(2.3) 15(1.1)
Level of health facility
HCII + HCIII 1,5404(15.0) 14,757(16.0) 376(11.0) 85(6.0)
HCIV + General hospital 26,102(26.0) 24,713(26.0) 969(28.0) 155(11.0)
Specialized HIV cares services 13,944(14.0) 13,224(14.0) 398(11.0) 146(10.0)
RRH + NRH 45,203(45.0) 42,047(44.0) 1747(50.0) 1050(73.0)
Denominator for pregnant/breastfeeding mothers was total females in the sample.
HCII health centre two, HCIII health centre three, HCIV health centre four, RRH regional referral hospitals, NRH national referral hospitals
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Table 2 Proportion of HIV patients on ART with virological non-suppression, (N = 100,678, routine monitoring, n = 94,766, suspected
treatment failures, n = 3492 and second time testers, n = 1436)
Variable Non-suppression status, n(%)
General Routine monitoring Suspected treatment
failures
Repeater testers after
suspected failure
Overall 10,805 (11) 8966(10) 1018(29) 716(50)
Sex
Female 6524(10) 5437(9) 592(31) 427(47)
Male 4132(13) 3402(11) 416(27) 278(54)
Age category
0–4 507(29) 444(27) 22(49) 34(52)
5–9 916(23) 754(21) 55(50) 104(60)
10–14 960(23) 765(20) 83(61) 105(63)
15–19 837(27) 614(23) 102(54) 118(66)
20–24 746(16) 595(13) 81(46) 65(50)
25–29 1141(11) 945(9) 117(46) 65(50)
30–34 1579(10) 1337(9) 154(35) 70(44)
35+ 4119(7) 3512(7) 404(19) 155(36)
Breast feeding
Yes 297(6) 262(6) 22(42) 14(40)
No 5964(10) 8420(10) 956(29) 679(50)
Pregnant
Yes 153(8) 128(7) 13(48) 14(42)
No 6113(10) 8554(10) 966(29) 681(50)
Active TB
Yes 131(20) 85(15) 34(44) 12(80)
No 10,236(11) 8542(9) 932(29) 684(50)
Treatment line
First 9945(11) 8351(9) 925(29) 582(54)
Second 736(13) 531(11) 75(28) 128(36)
Third 11(22) 4(10) 3(75) 3(75)
Duration on treatment
0–2 Years 3680(10) 3198(9) 291(29) 133(45)
3–5 Years 3900(12) 3226(10) 386(31) 264(48)
6–10 Years 2928(10) 2304(9) 309(28) 294(55)
> 10 Years 257(9) 210(8) 24(19) 22(42)
Indication for treatment initiation
TB infection 194(13) 159(11) 19(26) (16(67)
Other 604(15) 466(13) 49(38) 77(61)
Child under 15 1826 (24) 1508 (21) 135(58) 170(57)
PMTCT/Option B+ 589(6) 549(6) 18(22) 12(20)
CD4 < 500 7169(10) 5955(9) 750(26) 401(48)
Reported adherence level
< 85% 453(35) 324(34) 85(34) 38(61)
85–94% 1659(17) 1206(14) 269(32) 168(58)
> 95% 8145(10) 6998(9) 622(27) 465(46)
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Factors associated with virological non-suppression:
Sub-group analysis
In a sub-group analysis of the factors associated with
virological non-suppression among suspected treatment
failures and repeat testers after suspected failure, we
found that, among suspected treatment failures, breast
feeding (ORcrude = 1.8, 95%CI = 1.0–3.2) and pregnancy
(ORcrude = 2.3, 95%CI = 1.1–4.9) increased the odds of
being virologically non-suppressed (at bivariate analysis
level). On the other hand, among repeat testers after
suspected failure, having active TB was associated with
the highest odds of virological non-suppression
(ORadj = 7.0, 95%CI = 1.4–32.1).
Discussion
In this descriptive cross-sectional study conducted to es-
timate the proportion of patients virologically non-
suppressed and to identify the factors associated with
virological non-suppression, we found an overall propor-
tion of non-suppression of 11%. Amongst the 3 sub-
patient categories, patients on routine monitoring regis-
tered the lowest while repeat testers after suspected
failure registered the highest proportion of non-
suppressed patients. Being a suspected treatment failure,
repeat tester after suspected treatment failure, young
age, poor adherence and having active TB increased the
odds of virological non-suppression. Being on second/
third line treatment decreased the odds of virological
non-suppression. Repeater testers after suspected failure
with active TB registered the highest odds of non-
suppression compared to TB patients amongst other
sub-categories.
Although our study reveals the overall proportion of
non-suppressed patients being relatively low, we observe
sub-groups such as children and adolescents, patients
with adherence level < 85%, patients with active TB, and
repeat testers after suspected failure having relatively
higher virological non-suppression levels. This calls for
MOH to enhance efforts in the identified sub-groups to
improve virological suppression.
Our findings show that repeat testers after suspected
failure registered the highest non-suppression. Although
the Uganda viral load monitoring guidelines recommend
enhanced adherence counseling and support for patients
whose first VL result is beyond the threshold, it is not
clear whether the health care system is giving enough at-
tention to these patients. The Uganda guidelines recom-
mend use of text messages for adherence fostering.
Other countries like Swaziland have developed and im-
plemented targeted adherence support tools which rec-
ommend more frequent clinic reviews (1-monthly drug
pick-ups from 3-monthly pick-ups), stepped-up adher-
ence counseling (3 sessions) and education on the value
for VL testing among other interventions. However, des-
pite the use of a standard tool in Swaziland, there was
no difference in the non-suppression rate amongst the
re-testers which the authors associated with weaknesses
in the counseling training and supervision [6]. Although
WHO recommends adherence interventions for patients
with detectable VL, no specification was given on the
exact interventions to be undertaken [20]. Therefore, de-
signing more efficient and effective follow up mecha-
nisms for such patients is crucial. Further, it is critical to
identify and answer key quality of care questions, such
as: a) what happens when a VL result is received at a
health facility?, b) do health care workers and patients
understand the meaning and implication of different VL
results?, c) are patients whose VL result is beyond the
threshold given priority?, and d) are there any quality
improvement interventions for such patients?
An elevated VL indicates poor adherence or resistance
[21–25]. The current Uganda Ministry of Health viral
load monitoring algorithm requires confirmatory testing
after 6 months in the event of an elevated initial test
[19]. This may lead to unnecessary delay in treatment
switch for patients harboring resistance. Delaying ART
switch for patients with resistance increases the risk of
sexual transmission of ART-resistant strains [26–28], as
well as the likelihood of subsequent failure on second-
line therapy [21–24, 29] [30–32]. Therefore, the Ministry
of Health should consider adopting resistance testing for
persons with viral loads beyond the threshold or elevated
viral loads. This will facilitate early identification of re-
sistance and subsequent regimen switch.
We found that children and young adolescents were
significantly more likely to be non-suppressed compared
Table 2 Proportion of HIV patients on ART with virological non-suppression, (N = 100,678, routine monitoring, n = 94,766, suspected
treatment failures, n = 3492 and second time testers, n = 1436) (Continued)
Level of health facility
HCII + HCIII 1455(9) 1295(9) 104(28) 36(42)
HC IV + General hospital 2293(9) 1994(8) 228(24) 39(25)
Specialized HIV care services 1482(11) 1242(9) 148(37) 83(57)
RRH + NRH 5575(12) 4435(11) 538(31) 558(53)
Denominator for pregnant/breastfeeding mothers was total females in the sample
HCII health centre two, HCIII health centre three, HCIV health centre four, RRH regional referral hospitals, NRH national referral hospitals
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Table 3 Factors associated with virological non-suppression among HIV patients on ART, August 2014–July 2015, (N = 100,678)
Variable Not suppressed (%) Suppressed (%) ORcrude(95%CI) ORadj(95%CI)
a
Reason for testing
Routine testing 8966(84) 8966(96) 1.0 1.0
Suspected treatment failure 1018(10) 2474(3.0) 4.2(3.6–4.2) 3.3(3.0–3.6)
Repeat testers after suspected failure 716(6) 720(1.0) 9.5(8.6–10) 6.3(5.5–7.2)
Age category
35+ 4119(38) 52,527(59) 1.0 1.0
34–30 1579(15) 13,915(16) 1.4(1.4–1.5) 1.6(1.5–1.7)
29–25 1141(11) 9554(11) 1.5(1.4–1.6) 1.9(1.7–2.0)
24–20 746(7) 4035(5) 2.4(2.2–2.6) 2.7(2.5–3.0)
19–15 837(8) 2248(3) 4.7(4.4–5.2) 4.1(3.7–4.6)
14–10 960(9) 3271(4) 3.7(3.5–4.1) 3.3(2.9–3.7)
9–5 916(9) 3067(3) 3.8(3.5–4.1) 3.4(3.1–3.8)
4–0 507(5) 1256(1) 5.1(4.6–5.7) 5.3(4.6–6.1)
Indication for treatment initiation
PMTCT/Option B+ 589(6) 9231(11) 1.0 1.0
Child <15 Years 1826(19) 5886(7) 4.9(4.4–5.6) 2.1(1.9–2.4)
TB infection 194(2) 1302(2) 2.3(1.9–2.8) 2.1(1.8–2.6)
CD4 < 500 7169(73) 67,232(80) 1.7(1.5–1.8) 2.0(1.8–2.2)
ARV adherence
> 95% 8145(79) 77,295(89) 1.0 1.0
85–94% 1659(17) 8406(8) 1.9(1.8–2.0) 1.6(1.5–1.7)
< 85% 453(4) 839(1) 5.1(4.6–5.8) 3.4(2.9–3.9)
Treatment line
First line 9945(93) 8453(95) 1.0 1.0
Second/Third line 747(7) 4800(5) 1.3(1.3–1.4) 0.86(0.78–0.95)
Sex
Female 6524(61) 60,573(68) 1.0 1.0
Male 4132(39) 28,071(32) 1.4(1.3–1.4) 1.2(1.1–1.3)
Active TB
No 1,0236(99) 86,650(99) 1.0 1.0
Yes 131(1) 537(1) 2.1(1.7–2.5) 1.9(1.6–2.4)
Health Facility Level
HCII + HCIII 1455(13) 13,949(16) 1.0 1.0
HCIV + General hospital 2293(21) 23,809(27) 0.92(0.86–0.99) 0.89(0.82–0.97)
Specialized HIV services 1482(14) 12,462(14) 1.1(1.1–1.2) 1.2(1.1–1.3)
RRH + NRH 5575(52) 39,628(44) 1.3(1.3–1.4) 1.0(0.96–1.1)
Duration on treatment
0–2 Years 3680(34) 32,661(36) 1.0 1.0
3–5 Years 3900(36) 29,028(32) 1.2(1.1–1.3) 1.3(1.2–1.4)
6–10 Years 2928(27) 2549(28) 1.0(0.97–1.1) 1.1(1.1–1.2)
> 10 Years 257(3) 2469(4) 0.92(0.81–1.1) 0.91(0.78–1.1)
Breast feeding
No 5964(95) 54,369(93) 1.0
Yes 297(5) 4400(8) 0.61(0.54–0.69) −
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to the rest of the age groups. Similarly, a recent study
conducted in the US reported that older patients were
more likely to achieve viral suppression [33]. Treatment
for children and adolescents presents several challenges
including the complexity in ARV dosing and the need to
adjust doses as the children grow, which may be difficult
especially for providers who are not skilled enough with
pediatric care or too busy to track the suppression sta-
tus. Treatment for children may also be affected by the
type of caretakers for the child (i.e. parents vs. other
caretakers), schooling environment (for those in
schools), and transition to adolescent [34, 35]. Stigma,
fear of disclosure, and stress may affect younger people
more than their older counterparts [36–38]. Keeping
young people in care by using social workers, peer sup-
porters, and training on pediatric disclosure among
health workers has been reported to contribute to im-
proved ART adherence and hence better virological out-
comes [39]. Alcohol, recreational drug use, and low
socioeconomic status also contribute to non-adherence
and hence virological failure among the young people
[40, 41].
Our findings reveal that virological non-suppression is
a common phenomenon even among people with good
adherence, which highlights the need to ensure wide
coverage and access to viral load testing services. This
requires huge investments in viral load laboratory testing
infrastructure and services, including point of care diag-
nostics especially in hard to reach areas. Further, a suffi-
cient pool of trained providers is key to ensuring proper
tracking, timely viral loads and quick action (including
adherence support) based on the results.
HIV-associated TB is common among people on ART
in Africa [42]. A number of cross-sectional studies have
highlighted a link between incident TB and virological
non-suppression [43–46]. However, the causality may
not be clear given the inherit weaknesses of cross-
sectional studies. It is possible for virological failure to
lead to incident TB.The risk of virological non-
suppression may also be increased by concurrent ART
and TB treatment majorly due to impaired treatment ad-
herence and pharmacokinetics drug interactions. Pa-
tients on ART with active TB should thus be prioritised
for viral load monitoring and adherence support.
Strengthening; interventions that prevent incident TB
during ART such as isoniazid prevent therapy and infec-
tion control at health facilities is crucial. Repeat testers
after suspected failure with active TB registered the
highest risk of non-suppression compared to TB patients
amongst other sub-categories (for routine monitoring
and suspected treatment failures). Repeat testers after
suspected failure pending confirmation, are more likely
not to adhere to their medicines and therefore being at
highest risk for virological non-suppression compared to
other sub-groups. In-addition, the 74% reported adher-
ence level for these patients could partly explain this
finding.
Limitations
The major limitation with our study was use of program
data which had missing records. To enhance data qual-
ity, the laboratory is attempting to reduce this gap by
making immediate phone calls to facilities where the
samples are derived from. The cross-sectional study de-
sign may have misclassified transient viraemia as ‘non-
suppressor’ leading to higher proportions of patients
with virological non-suppression. In-addition, the cross-
sectional study design, could not allow causality to be
established. Clustering due to repeated samples in the
same individual may have influenced the results in either
direction. However, because of inconsistencies in the
numbering of samples, we were not able to identify any
repeat testers; and for this reason, we were not able to
account for clustering effect in the analysis. In addition,
although many studies have identified patient’s CD4
count as one of the major factors associated with viro-
logical suppression, we did not assess it in our study.
This was due to the fact that the data collection tool that
was used to collect the data analyzed in this study did
not have an option for patients’ current CD4 count. The
other limitation is that there could have been selection
bias arising from the fact that the samples with complete
records could have been obtained from individuals who
were more motivated to seek viral load testing; or that
patients who were tested could have been more likely to
be non-suppressors. However, given that we used sec-
ondary data, it is very difficult to tell the extent to which
selection bias exists or affects the interpretation of
Table 3 Factors associated with virological non-suppression among HIV patients on ART, August 2014–July 2015, (N = 100,678)
(Continued)
Pregnant
No 6113(98) 56,841(97)
Yes 153(2) 1856(3) 0.77(0.65–0.91) −
Denominator for pregnant/breastfeeding mothers was total females in the sample
HCII health centre two, HCIII health centre three, HCIV health centre four, RRH regional referral hospitals, NRH national referral hospitals
aWe adjusted for age, sex, ARV adherence, treatment line (first, second/third), identification for treatment initiation at baseline (ePMTCT option B+, child under 15,
CD4 < 500 and TB infection), having active TB, duration on treatment, and health facility level
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results. Our overall non-suppression level of 11% (sup-
pression of 89%) suggests that Uganda is close to achiev-
ing the 90% viral suppression which is the UNAIDS
target among HIV infected individuals on treatment.
However, our study sample was only 100, 678 HIV-
positive individuals versus the 750,896 individuals who
were on active ART by the end of 2014 [18]. Thus, our
findings may not be fully representative of the entire
population on ART in Uganda.
The strength of this study was its large sample size
and data on samples derived at the national level and
thus provides a national outlook on the critical challenge
of non-suppression amongst different populations re-
ceiving ART. This study identifies populations that re-
quire enhanced and targeted interventions to optimize
ART and raises questions for additional research in this
field.
Conclusion
Repeat testers after suspected failure registered the high-
est proportion of non-suppressed patients. Young age,
poor adherence and having active TB increased the odds
of virological non-suppression. Being on second/third
line regimens was protective against non-suppression.
We recommend close follow up and intensified targeted
adherence support for suspected treatment failures, re-
peat testers after suspected failure, children and adoles-
cents, and adherence to ART guidelines by ART clinics.
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